在接受 Targeted OncologyTM 采访时，Memorial Sloan Kettering Cancer Center 的医学肿瘤学家 Ghassan K. Abou-Alfa 医学博士讨论了目前影响该领域的 HCC 领域的 3 个最新摘要。作者: StephenW 时间: 2022-10-7 12:42
Clinical Trial Results Allude to New Options for Patients With HCC
October 7, 2022
Jordyn Sava
In an interview with Targeted Oncology, Ghassan K. Abou-Alfa, MD, discussed 3 late breaking abstracts in the hepatocellular carcinoma space currently influencing the field.
figure image
The hepatocellular carcinoma (HCC) space has been presented with a number of trials exploring immune-oncology (IO) therapies combined with VEGF antibodies, tyrosine kinase inhibitors (TKIs), and more over the past 5 years.
Currently, more than 1 standard-of-care option exists in this space, including the combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) or regorafenib (Stivarga) in the first-line setting, and camrelizumab (AiRuiK), or nivolumab (Opdivo), ipilimumab (Yervoy), and ramucirumab (Cyramza) in the second-line setting.
Even though many options are available, investigators continue to look for better outcomes for their patients. This includes investigating novel therapies alone and adding onto the standard-of-care regimens.
Updated data from trials evaluating new options in HCC were discussed in 3 late breaking abstracts presented at the European Society for Medical Oncology (ESMO) Congress 2022.
These trials included the phase 3 RATIONALE-301 (NCT03412773) study of frontline tislelizumab vs sorafenib, a phase 3 study (NCT03764293) examining the PD-1 inhibitor camrelizumab combined with rivoceranib, and the phase 3 LEAP-002 study (NCT03713593) of lenvatinib plus pembrolizumab (Keytruda).
In an interview with Targeted OncologyTM, Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed 3 late breaking abstracts in the HCC space currently influencing the field.作者: StephenW 时间: 2022-10-7 12:42